

COVID-19 Vaccine Recommendations

Immunocompromised Adults and Adolescents: Administration of Primary Series and Booster Doses

Date: June 20, 2022



	Dose 1 (primary)		Dose 2 (primary)		Dose 3 (additional dose) (primary)		Dose 4 (booster 1)		Dose 5 (booster 2)
Pfizer (gray or purple cap) Ages 12 and older	0.3 mL	Wait 3 weeks →	0.3 mL	Wait 4 weeks →	Pfizer: 0.3 mL OR Moderna: 0.5 mL	Wait 3 months →	Pfizer: 0.3 mL OR Moderna: 0.25 mL OR J&J: 0.5 mL	Wait 4 months → Eligible Patients: - Ages 50 and older - Ages 12 years and older who are moderately to severely immunocompromised	Pfizer: 0.3 mL OR Moderna: 0.25 mL
Moderna (red cap) Ages 18 and older	0.5 mL	Wait 4 weeks →	0.5 mL	Wait 4 weeks →	Pfizer: 0.3 mL OR Moderna: 0.5 mL	Wait 3 months →	Pfizer: 0.3 mL OR Moderna: 0.25 mL OR J&J: 0.5 mL	Wait 4 months → Eligible Patients: - Ages 50 and older - Ages 18 years and older who are moderately to severely immunocompromised	Pfizer: 0.3 mL OR Moderna: 0.25 mL
	Dose 1 (primary)			Dose 2 (additional dose) (primary)		Dose 3 (booster 1)		Dose 4 (booster 2)	
J & J Ages 18 and older	0.5 mL	Wait 4 weeks →		Pfizer: 0.3 mL OR Moderna: 0.5 mL	Wait 2 months →	Pfizer: 0.3 mL OR Moderna: 0.25 mL OR J&J: 0.5 mL	Wait 4 months → Eligible Patients: - Ages 50 and older - Ages 18 years and older who are moderately to severely immunocompromised - Ages 18–49 years who received 2 previous doses of J&J	Pfizer: 0.3 mL OR Moderna: 0.25 mL NOTE: J&J may NOT be used as a 2nd booster	

NOTE: J&J should only be used in limited situations and cannot be used as a second booster.